8-KMaterial AgreementsOther EventsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jun 29, 2011)

Filed June 29, 2011For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on June 29, 2011, detailing a material definitive agreement and other events. The company has extended a Sponsored Research Agreement with The University of British Columbia (UBC) and AlCana Technologies, Inc. (AlCana) for a third year, through July 2012. This agreement focuses on discovering novel lipids for use in lipid nanoparticle (LNP) formulations, crucial for the systemic delivery of RNAi therapeutics. Alnylam has secured exclusive rights to new inventions related to oligonucleotide and nucleic acid construct delivery, along with sole rights to sublicense resulting intellectual property. In addition, Alnylam announced its filing of an Answer and Counterclaim on June 28, 2011, in a legal action initiated by Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics, Inc. The legal dispute's specifics are not detailed in this 8-K, but the filing indicates Alnylam's active engagement in defending its position. This development, alongside the continued investment in LNP delivery technology, is a key point for investors monitoring Alnylam's strategic progress and potential legal headwinds.

Key Highlights

  • 1Alnylam has extended its Sponsored Research Agreement with UBC and AlCana for a third year, through July 2012, to advance LNP formulation technology.
  • 2The research focuses on novel lipids for improved systemic delivery of RNAi therapeutics, a core area for Alnylam's platform.
  • 3Alnylam has secured exclusive rights to new inventions and sublicense rights for intellectual property arising from this research collaboration.
  • 4The company is eligible to receive up to $1.325 million in milestone payments and single-digit royalties per Licensed Product based on the agreement.
  • 5A Supplemental Agreement with Tekmira and Protiva includes terms regarding intellectual property and grants specific rights for Tekmira/Protiva's RNAi programs.
  • 6Alnylam filed an Answer and Counterclaim on June 28, 2011, in a lawsuit brought by Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics, Inc.
  • 7The lawsuit involves a dispute related to the Business Litigation Section of the Suffolk County Superior Court in Boston, Massachusetts.

Frequently Asked Questions

The Extended Sponsored Research Agreement between Alnylam, UBC, and AlCana is focused on the discovery of novel lipids to be used in lipid nanoparticle (LNP) formulations. The goal is to enhance the systemic delivery of RNAi therapeutics, which is a critical component of Alnylam's drug development strategy.

Alnylam has exclusive rights to all new inventions related to the delivery of oligonucleotides and other nucleic acid constructs arising from the research. The company also holds sole rights to sublicense any resulting intellectual property to its collaborators.

Alnylam filed an Answer and Counterclaim on June 28, 2011, in response to a First Amended Complaint filed by Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics, Inc. The specific details of the dispute are not elaborated in this 8-K filing, but it indicates an ongoing legal proceeding.

UBC and AlCana are eligible to receive up to an aggregate of $1.325 million in milestone payments for each Licensed Product directed to a particular Target, in addition to single-digit royalty payments on annual product sales.